Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
25.15
USD
|
0.00%
|
|
-3.27%
|
+24.14%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,098
|
705.1
|
719.4
|
866.2
|
1,300
|
-
|
-
|
Enterprise Value (EV)
1 |
821.4
|
457.3
|
505.9
|
617.1
|
798.4
|
896.9
|
1,101
|
P/E ratio
|
-4.7
x
|
-8.54
x
|
-6.69
x
|
-7.85
x
|
-8.29
x
|
-8.52
x
|
-8.04
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
80.7
x
|
39.1
x
|
230
x
|
41.8
x
|
358
x
|
210
x
|
651
x
|
EV / Revenue
|
60.3
x
|
25.4
x
|
162
x
|
29.8
x
|
220
x
|
145
x
|
551
x
|
EV / EBITDA
|
-14.9
x
|
-6.55
x
|
-4.7
x
|
-5.68
x
|
-4.88
x
|
-3.9
x
|
-3.83
x
|
EV / FCF
|
-15.8
x
|
-
|
-5.15
x
|
-7.85
x
|
-4.73
x
|
-5.27
x
|
-5.97
x
|
FCF Yield
|
-6.32%
|
-
|
-19.4%
|
-12.7%
|
-21.2%
|
-19%
|
-16.8%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
26,494
|
32,139
|
32,392
|
42,754
|
51,703
|
-
|
-
|
Reference price
2 |
41.45
|
21.94
|
22.21
|
20.26
|
25.15
|
25.15
|
25.15
|
Announcement Date
|
3/25/21
|
3/28/22
|
3/15/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
13.61
|
18.04
|
3.129
|
20.72
|
3.632
|
6.184
|
1.997
|
EBITDA
1 |
-55.22
|
-69.81
|
-107.6
|
-108.7
|
-163.5
|
-229.8
|
-287.1
|
EBIT
1 |
-56.66
|
-71.33
|
-110
|
-112.9
|
-165.9
|
-211.2
|
-236.6
|
Operating Margin
|
-416.28%
|
-395.46%
|
-3,516.52%
|
-544.65%
|
-4,568%
|
-3,415.74%
|
-11,845.12%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-107.5
|
-100.8
|
-152.3
|
-172.3
|
-186.9
|
Net income
1 |
-56.69
|
-71.32
|
-107.5
|
-100.8
|
-158.2
|
-191.2
|
-186.9
|
Net margin
|
-416.49%
|
-395.37%
|
-3,435.41%
|
-486.59%
|
-4,357.03%
|
-3,091.78%
|
-9,359.8%
|
EPS
2 |
-8.820
|
-2.570
|
-3.320
|
-2.580
|
-3.032
|
-2.952
|
-3.127
|
Free Cash Flow
1 |
-51.91
|
-
|
-98.22
|
-78.56
|
-169
|
-170.1
|
-184.3
|
FCF margin
|
-381.35%
|
-
|
-3,139.05%
|
-379.11%
|
-4,652.18%
|
-2,751%
|
-9,229.87%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/25/21
|
3/28/22
|
3/15/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.092
|
1.219
|
0.162
|
0.5
|
1.247
|
0.298
|
0.239
|
20.2
|
-0.019
|
0.028
|
1.039
|
1.06
|
1.565
|
0.5
|
0.5
|
EBITDA
|
-24.37
|
-
|
-27.96
|
-
|
-
|
-29.08
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-24.76
|
-26.39
|
-28.43
|
-26.5
|
-28.72
|
-30.11
|
-32.14
|
-13.97
|
-36.65
|
-38.14
|
-40.14
|
-42.52
|
-45.22
|
-48
|
-53
|
Operating Margin
|
-26,917.39%
|
-2,165.05%
|
-17,546.91%
|
-5,299%
|
-2,303.13%
|
-10,102.68%
|
-13,446.03%
|
-69.16%
|
192,905.26%
|
-136,200%
|
-3,862.32%
|
-4,009.88%
|
-2,889.1%
|
-9,600%
|
-10,600%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-28.09
|
-25.69
|
-27.38
|
-28.68
|
-29.62
|
-10.26
|
-32.28
|
-32.4
|
-37.26
|
-38.81
|
-40.44
|
-
|
-
|
Net income
1 |
-25.08
|
-26.34
|
-28.09
|
-25.69
|
-27.38
|
-28.68
|
-29.62
|
-10.26
|
-32.28
|
-32.4
|
-37.11
|
-39.12
|
-46.54
|
-
|
-
|
Net margin
|
-27,264.13%
|
-2,160.62%
|
-17,337.04%
|
-5,138.2%
|
-2,195.59%
|
-9,624.83%
|
-12,391.63%
|
-50.76%
|
169,910.53%
|
-115,717.86%
|
-3,570.21%
|
-3,689.84%
|
-2,972.96%
|
-
|
-
|
EPS
2 |
-0.8500
|
-0.8200
|
-0.8700
|
-0.7900
|
-0.8400
|
-0.8800
|
-0.7700
|
-0.2400
|
-0.7700
|
-0.6600
|
-0.7467
|
-0.7867
|
-0.9300
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/28/22
|
5/12/22
|
8/11/22
|
11/8/22
|
3/15/23
|
5/10/23
|
8/9/23
|
11/9/23
|
2/29/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
277
|
248
|
214
|
249
|
502
|
403
|
200
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-51.9
|
-
|
-98.2
|
-78.6
|
-169
|
-170
|
-184
|
ROE (net income / shareholders' equity)
|
-61.8%
|
-24.8%
|
-39.1%
|
-37.4%
|
-44.6%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-7.920
|
-2.490
|
-2.680
|
-1.940
|
-
|
-
|
-
|
Capex
1 |
1
|
-
|
11.5
|
2.77
|
4.49
|
4.53
|
4.58
|
Capex / Sales
|
7.35%
|
-
|
368.68%
|
13.37%
|
123.57%
|
73.3%
|
229.27%
|
Announcement Date
|
3/25/21
|
3/28/22
|
3/15/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
25.15
USD Average target price
52.3
USD Spread / Average Target +107.95% Consensus |
1st Jan change
|
Capi.
|
---|
| +24.14% | 1.3B | | +67.53% | 63.85B | | -0.77% | 41.83B | | +44.98% | 40.47B | | -10.87% | 27.17B | | +13.30% | 26.52B | | -22.79% | 18.69B | | +4.70% | 12.73B | | +24.10% | 12.11B | | +27.41% | 12.07B |
Other Biotechnology & Medical Research
|